Clavis Pharma (OSE: CLAVIS); the Norwegian cancer drug development company, announced today that the US Food & Drug Administration (FDA) has granted orphan drug designation to CP-4126 for the treatment of pancreatic cancer. The designation follows the equivalent designation given by the European...